Social BehaviorNCT02963194
Oxytocin Effects on Self and Other Processing
A study testing Oxytocin in people with Social Behavior, run by University of Electronic Science and Technology of China at 1 site in China.
Trial summary
To determine whether the neuropeptide oxytocin (OXT) influences self-processing by investigating whether it increases the endowment effect in relation to both self and others. Read more about this study
- Who is it for?
- Ages 18 to 27 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Social Behavior
- What is being tested?
- Oxytocin
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 44 participants
- Where
- 1 siteChina
- Study dates
- Nov 2015to Jun 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 27 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- healthy subjects without past or current psychiatric or neurological disorders
Who cannot join
- history of head injury;
- claustrophobia;
- medical or psychiatric illness.
Trial locations and contacts
1 site in 1 country.
China1 site
School of Life Science and Technology, University of Electronic Science and Technology
Chengdu, Sichuan, 611731
About this study
To determine whether the neuropeptide oxytocin (OXT) influences self-processing by investigating whether it increases the endowment effect in relation to both self and others.
Read the detailed description
In a double-blind, between- subject placebo (PLC) controlled design, investigator aimed to measure the effect of intranasal OXT on the endowment effect. All subjects completed a range of questionnaires measuring personality and affective traits and levels of anxiety before self-administration: Positive and Negative Affect Schedule (PANAS) , State-Trait Anxiety Inventory (STAI) , Beck Depression Inventory (BDI), self-esteem scale (SES). Subjects were asked to decide whether to buy or sell their own or others' (their mothers'/ fathers'/ classmate'/ strangers') possessions at various prices. Indifference point and brain activation were inluded into analysis as dependent variables.
- Conditions
- Social Behavior
- Being tested
- Oxytocin, Placebo
- Keywords
- self-processing, endowment effect, neuroimage
- Medical subject headings
- Social Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OxytocinDrug
PlaceboDrug
| Study group | Role | What they receive |
|---|---|---|
| Oxytocin | Experimental | Oxytoxin nasal spray Receives: Drug: Oxytocin |
| Placebo | Placebo comparator | Placebo nasal spray Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compared the indifference point between buy and sell conditions during the price phase and the specific brain region activation between oxytocin and placebo groups
Indifference point is the gap between willingness to accept and willingness to pay ;focus on the specfic brain region relasted to self-processing, such as medial prefrontal cortex, precuneus, posterior cingulate cortex, ventral striatum.
Measured: 1 hour
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Nov 2016 (estimated)
- Study startNov 2015
- Primary completionMar 2016
- Study completionJun 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Social BehaviorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 44 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Electronic Science and Technology of China
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Keith Kendrick, Dr., Principal investigator, University of Electronic Science and Technology of China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02963194
- Sponsor's protocol ID
- UESTC-neuSCAN-05
- Status last verified
- Nov 2016
- First submitted
- 15 Apr 2016
- Last updated
- 15 Nov 2016
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Nov 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Oxytocin Effects on Self and Other Processing
- ClinicalTrials.gov ID
- NCT02963194
- Acronym / sponsor ID
- UESTC-neuSCAN-05
- Conditions
- Social Behavior
- Keywords
- self-processing, endowment effect, neuroimage
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 44 participants (actual)
- Lead sponsor
- University of Electronic Science and Technology of ChinaUniversity, hospital or other
- Study start
- Nov 2015
- Primary completion
- Mar 2016 (actual)
- Study completion
- Jun 2016 (actual)
- First posted
- 15 Nov 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine whether the neuropeptide oxytocin (OXT) influences self-processing by investigating whether it increases the endowment effect in relation to both self and others.
Detailed description
In a double-blind, between- subject placebo (PLC) controlled design, investigator aimed to measure the effect of intranasal OXT on the endowment effect. All subjects completed a range of questionnaires measuring personality and affective traits and levels of anxiety before self-administration: Positive and Negative Affect Schedule (PANAS) , State-Trait Anxiety Inventory (STAI) , Beck Depression Inventory (BDI), self-esteem scale (SES). Subjects were asked to decide whether to buy or sell their own or others' (their mothers'/ fathers'/ classmate'/ strangers') possessions at various prices. Indifference point and brain activation were inluded into analysis as dependent variables.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Oxytocin | Experimental | Drug: OxytocinOxytoxin nasal spray |
| Placebo | Placebo comparator | Drug: PlaceboPlacebo nasal spray |
Who may qualify
- Ages
- 18 to 27 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- healthy subjects without past or current psychiatric or neurological disorders
Key exclusion criteria (3 listed)
- history of head injury;
- claustrophobia;
- medical or psychiatric illness.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Oxytocin | Drug | Oxytocin |
| Placebo | Drug | Placebo |
Primary outcome
Compared the indifference point between buy and sell conditions during the price phase and the specific brain region activation between oxytocin and placebo groups
Time frame: 1 hour
Indifference point is the gap between willingness to accept and willingness to pay ;focus on the specfic brain region relasted to self-processing, such as medial prefrontal cortex, precuneus, posterior cingulate cortex, ventral striatum.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Nov 2016.
Related trials for Social Behavior
Not yet recruiting
AI-Based CBT Chatbot for Adolescent Social Anxiety
AI-CBT Intervention Group, Waitlist Control Group
Not yet recruiting
Integrated Psychoeducation Program for Internalized Stigma in Schizophrenia
Schizophrenia, Schizoaffective Disorder
Active, not recruiting
Keep Social Randomized Controlled Trial for Young Adults With Cancer
Cancer
Not yet recruiting
Hybrid Type 1 Trial of a Parent-Based Intervention Addressing Social Media and Adolescent Alcohol Use
Adolescent Alcohol Use
Not yet recruiting
Evaluation of a Novel Quantum-Inspired Intervention (QII) for Children With Autism Spectrum Disorder: A Global Confirmatory Study
Autism Spectrum Disorder, Autism Spectrum Disorder (ASD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Keith Kendrick, Dr. principal investigator
University of Electronic Science and Technology of China
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Oxytocin in people with Social Behavior, run by University of Electronic Science and Technology of China at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Nov 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compared the indifference point between buy and sell conditions during the price phase and the specific brain region activation between oxytocin and placebo groups (time frame: 1 hour). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2016.